All lobbying filings

KELLEY DRYE & WARREN LLP

Lobbying for LABORATORY CORPORATION OF AMERICA HOLDINGS · Clinical laboratory

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$110,000.00

What the client paid this registrant for the period.

Client based in

North Carolina

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 6

HR 5269
RESULTS Act
S 2761
RESULTS Act
HR 5582
Patients Deserve Price Tags Act
S 2355
Patients Deserve Price Tags Act
HR 9393
Lower Costs, More Transparency Act of 2026
HR 8890
Enhancing CLIA Act of 2026

Lobbying activity 1

Health Issues

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.